2-(4-(4-aminobutyl)thiazol-2-yl)guanidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-(4-aminobutyl)thiazol-2-yl)guanidine
• 英文别名: 2-(2-guanidino)-4-(4-aminobutyl)-thiazole；4-(2-guanidinothiazol-4-yl)butylamine；2-Guanidino-4-(4-aminobutyl)thiazole；2-[4-(4-aminobutyl)-1,3-thiazol-2-yl]guanidine
• 化学式: C₈H₁₅N₅S
• 分子量: 213.307
• InChiKey: SLKRPKDOFFHSCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-(4-aminobutyl)thiazol-2-yl)guanidine 在 ammonium hydroxide 、 三乙胺 作用下， 以 甲醇 、 水 为溶剂， 反应 12.0h， 生成 N-cyano-N'-[4-(2-guanidino-thiazol-4-yl)-butyl]-guanidine
  参考文献：
  名称：

  NOVEL COMPOUND, ORGANIC CATION TRANSPORTER 3 DETECTION AGENT, AND ORGANIC CATION TRANSPORTER 3 ACTIVITY INHIBITOR

  摘要：

  公开号：

  EP3018125B1
• 作为产物：
  描述：

  1,6-二氯-2-己酮 在 sodium azide 、 水 、 三苯基膦 作用下， 以 四氢呋喃 、 二甲基亚砜 、 丙酮 为溶剂， 反应 4.0h， 生成 2-(4-(4-aminobutyl)thiazol-2-yl)guanidine
  参考文献：
  名称：

  NOVEL COMPOUND, ORGANIC CATION TRANSPORTER 3 DETECTION AGENT, AND ORGANIC CATION TRANSPORTER 3 ACTIVITY INHIBITOR

  摘要：

  公开号：

  EP3018125B1

文献信息

• Haloguanidine compounds, pharmaceutical compositions and methods of use
  申请人：ICI Americas Inc.

  公开号：US04362728A1

  公开（公告）日：1982-12-07

  Compounds useful for inhibiting gastric acid secretion and for the treatment of peptic ulcers caused or exacerbated by gastric acidity having the following formula (I): ##STR1## in which R.sup.1 and R.sup.2, are H, C.sub.1-10 alkyl, C.sub.3-8 cycloalkyl or cycloalkylalkyl in which the alkyl part is C.sub.1-6 and the cycloalkyl part is C.sub.3-8, each of the alkyl, cycloalkyl and cycloalkylalkyls being optionally substituted by one or more halogens selected from F, Cl and Br, provided that at least one of R.sup.1 and R.sup.2 is a halogen substituted alkyl, cycloalkyl or cycloalkylalkyl and provided that there is no halogen substituent on the carbon directly attached to the nitrogen; and X, m, Y, n and R.sup.3 are as described in the specification; and the pharmaceutically-acceptable acid-addition salts thereof. Processes for producing compounds of formula (I), pharmaceutical compositions containing them, methods of utilizing such compositions and intermediates useful for synthesizing compounds of formula (I) are also described.

  用于抑制胃酸分泌和治疗由胃酸引起或加重的消化性溃疡的化合物具有以下结构式（I）：##STR1##其中R.sup.1和R.sup.2为H，C.sub.1-10烷基，C.sub.3-8环烷基或环烷基烷基，其中烷基部分为C.sub.1-6，环烷基部分为C.sub.3-8，每个烷基，环烷基和环烷基烷基可选择地被来自F、Cl和Br的一个或多个卤素取代，前提是R.sup.1和R.sup.2中至少有一个是卤素取代的烷基，环烷基或环烷基烷基，并且直接连接到氮的碳上没有卤素取代物；X，m，Y，n和R.sup.3如规范中所述；以及其药用可接受的酸加盐。还描述了制备结构式（I）化合物的方法，含有它们的药物组合物，利用这种组合物的方法以及用于合成结构式（I）化合物的中间体。
• Thiadiazole histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04471122A1

  公开（公告）日：1984-09-11

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组织名称为##STR1##的组织胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的含氮5-至9-成员完全饱和的杂环环；m为0到2的整数；n为2到4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其新型抗溃疡剂的无毒药用盐、水合物、溶剂合物或N-氧化物。披露了其制备的中间体和方法。
• Chemical compounds
  申请人：Bristol-Myers Company

  公开号：US04394508A1

  公开（公告）日：1983-07-19

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组胺H.sub.2-拮抗剂的化学结构为##STR1##，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的5至9成员完全饱和的含氮杂环环；m为0至2的整数；n为2至4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性的药学可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。揭示了其中间体和制备方法。
• Histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04510309A1

  公开（公告）日：1985-04-09

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2, n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组式为##STR1##的组胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的含氮杂环环的5到9成员完全饱和的环；m为0到2的整数，n为2到4的整数；Z为硫、氧或亚甲基；A为可选取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性药用可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。公开了其制备的中间体和方法。
• Guanidino imidazoles and thiazoles
  申请人：ICI Americas Inc.

  公开号：US04165377A1

  公开（公告）日：1979-08-21

  The invention relates to guanidine derivatives of imidazoles and thiazoles which are histamine H-2 antagonists and which inhibit the secretion of gastric acid, to methods for their manufacture, to pharmaceutical compositions containing them and to methods of using such guanidine derivatives and compositions. The guanidine derivatives are of the general formula I: ##STR1## in which X is S or NH, Y is CH.sub.2, a direct bond or a vinylene radical, m is 0 to 4 and n is 1 to 4, R.sup.1 is hydrogen, halogen or alkyl, R.sup.2 is hydrogen, alkyl, alkanoyl or aroyl, A is a 3,4-dioxocyclobuten-1,2-diyl radical or C.dbd.Z in which Z is O, S, NCN, NNO.sub.2, CHNO.sub.2, NCONH.sub.2, C(CN).sub.2, NCOR.sup.3, NCO.sub.2 R.sup.3, NSO.sub.2 R.sup.3 or NR.sup.4 in which R.sup.3 is alkyl or aryl and R.sup.4 is hydrogen or alkyl, B is alkoxy or alkylthio or NR.sup.5 R.sup.6 in which R.sup.5 and R.sup.6 are independently hydrogen, alkyl, alkenyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkylaminoalkyl or dialkylaminoalkyl; and the salts thereof.

  该发明涉及嘌呤和噻唑的胍衍生物，它们是组织胺H-2拮抗剂，可以抑制胃酸分泌，涉及它们的制备方法，含有它们的药物组合物，以及使用这种胍衍生物和组合物的方法。这些胍衍生物的一般化学式为I：在该式中，X为S或NH，Y为CH.sub.2，直接键或乙烯基基团，m为0至4，n为1至4，R.sup.1为氢、卤素或烷基，R.sup.2为氢、烷基、烷酰基或芳酰基，A为3,4-二氧代环丁-1,2-二基基团或C.dbd.Z，其中Z为O、S、NCN、NNO.sub.2、CHNO.sub.2、NCONH.sub.2、C(CN).sub.2、NCOR.sup.3、NCO.sub.2 R.sup.3、NSO.sub.2 R.sup.3或NR.sup.4，其中R.sup.3为烷基或芳基，R.sup.4为氢或烷基，B为烷氧基、烷硫基或NR.sup.5 R.sup.6，其中R.sup.5和R.sup.6独立地为氢、烷基、烯基、环烷基、羟基烷基、烷氧基烷基、烷基氨基烷基或二烷基氨基烷基；以及它们的盐。